Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today's News: Middle East.
Press releases published on May 20, 2025
Enlivex Selected to Present at Israeli BioMed 2025 Conference
GlobeNewswire
·
May 20, 2025
Presentation to highlight Allocetra™ and the therapeutic potential of macrophage reprogramming in inflammatory diseases Ness-Ziona, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage …
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase
GlobeNewswire
·
May 20, 2025
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, …
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase
GlobeNewswire
·
May 20, 2025
PRINCETON, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced …
Aventis Energy Provides Recent Exploration Insights at the Corvo Uranium Project
GlobeNewswire
·
May 20, 2025
VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Aventis Energy. (“Aventis” or the “Company”) (CSE: AVE | OTC: VBAMF), is pleased to provide a comprehensive summary of exploration insights and historical data gathered at its Corvo Uranium …
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event
GlobeNewswire
·
May 20, 2025
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity - Following recent …
Praxis Precision Medicines to Participate in Upcoming Conferences
GlobeNewswire
·
May 20, 2025
BOSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …
Philikos announces initiation of clinical Phase 1/2 study with T-Guard® in patients with systemic sclerosis
GlobeNewswire
·
May 20, 2025
NIJMEGEN, the Netherlands, May 20, 2025 (GLOBE NEWSWIRE) -- Philikos B.V., a Dutch biotechnology company developing antibody-based therapies to treat severe immune disorders, today announced that it has enrolled the first patient in a Phase 1/2 clinical …
Philikos kondigt de start aan van een klinische fase 1/2-studie met T-Guard® bij patiënten met systemische sclerose
GlobeNewswire
·
May 20, 2025
NIJMEGEN, the Netherlands, May 20, 2025 (GLOBE NEWSWIRE) -- Philikos B.V., een Nederlands biotechnologiebedrijf dat op antilichamen gebaseerde therapieën ontwikkelt voor de behandeling van ernstige immuunziekten, heeft vandaag aangekondigd dat de eerste …
Avicanna Announces Sponsorship of Pilot Phase II Clinical Study Osteoarthritis Pain
GlobeNewswire
·
May 20, 2025
TORONTO, May 20, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based …
Nexxen Issues a Reminder for its Upcoming Investor Day on May 22, 2025
GlobeNewswire
·
May 20, 2025
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, today issued a reminder to investors and …
Revival Gold Commences 2025 Field Work and Provides Operational Update
GlobeNewswire
·
May 20, 2025
TORONTO, May 20, 2025 (GLOBE NEWSWIRE) -- Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”) is pleased to announce the start of this year’s field work and provide an update on operational activities at the Company’s gold …
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
GlobeNewswire
·
May 20, 2025
- In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence of new-onset AF/AFL by 17% in the subgroup with no prior history of AF compared to placebo - In the …
Midland Commences a Gold Exploration Program on Its Caniapisc Au Project, James Bay
GlobeNewswire
·
May 20, 2025
MONTREAL, May 20, 2025 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to announce the start of an exploration program for gold on its Caniapisc Au project, and also present results from the 2024 till survey, in the Eeyou …
Midland commence un programme d’exploration aurifère sur son projet Caniapisc Au à la Baie James
GlobeNewswire
·
May 20, 2025
MONTRÉAL, 20 mai 2025 (GLOBE NEWSWIRE) -- Exploration Midland inc. (« Midland ») (TSX-V : MD) a le plaisir d’annoncer le début d’un programme d’exploration pour l’or sur son projet Caniapisc Au, ainsi que présenter les résultats des tills de 2024, dans les …
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome
GlobeNewswire
·
May 20, 2025
Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone provides 10 years of market exclusivity in Europe upon approval ASHBURN, Va., May 20, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. …
Beckley Psytech announces positive topline data from Part 2 of its Phase IIa study of BPL-003 (intranasal 5-MeO-DMT benzoate) in combination with SSRIs for treatment resistant depression
GlobeNewswire
·
May 20, 2025
Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and long-lasting antidepressant effect for up to three months after dosing. BPL-003 was well-tolerated and patients were able to be discharged within …
PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
GlobeNewswire
·
May 20, 2025
PETACH TIKVA, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, will participate in a webcast presentation and host one-on-one meetings …
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
GlobeNewswire
·
May 20, 2025
- Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and durable antidepressant effect for up to three months after dosing - BPL-003 was well-tolerated and patients were able to be discharged within an …
Apollo Silver Expands Calico Project Land Package by over 285%
GlobeNewswire
·
May 20, 2025
VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Apollo Silver Corp. (“Apollo” or the “Company”) (TSX.V: APGO, OTCQB: APGOF, Frankfurt: 6ZF0) is pleased to announce it has acquired 2,215 hectares (“ha”) of highly prospective claims contiguous …
Newcore Gold Drilling Intersects 4.41 g/t Gold over 24.0 Metres, including 9.08 g/t Gold over 10.0 Metres, at the Enchi Gold Project, Ghana
GlobeNewswire
·
May 20, 2025
Drilling Intersects Wide Zones of Higher-Grade Gold Mineralization at the Boin Gold Deposit VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Newcore Gold Ltd. ("Newcore" or the "Company") (TSX-V: NCAU, OTCQX: NCAUF) is pleased to announce …